Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ciprofibrate

Known as: 2-(4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic acid, 2-(P-(2,2-Dichlorocyclopropyl)Phenoxy)-2-Methylpropionic Acid, Propanoic Acid, 2-(4-(2,2-Dichlorocyclopropyl)Phenoxy)-2-Methyl- 
A fibrate derivative with antilipidemic activity.
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Clofibric AcidFibric AcidsHypolipidemic AgentsPeroxisome Proliferators

Narrower (2)

LipanorOroxadin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study
Abstract Several therapeutic agents and industrial chemicals induce liver tumors in rodents through the activation of the… Expand
Review
2007
Review
2007
PPARs, Obesity, and Inflammation
The worldwide prevalence of obesity and related metabolic disorders is rising rapidly, increasing the burden on our healthcare… Expand
  • figure 1
Highly Cited
2005
Highly Cited
2005
Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver.
Fibrates, such as ciprofibrate, fenofibrate, and clofibrate, are peroxisome proliferator-activated receptor-alpha (PPARalpha… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2004
Highly Cited
2004
Application of comparative functional genomics to identify best-fit mouse models to study human cancer
Genetically modified mice have been extensively used for analyzing the molecular events that occur during tumor development. In… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Highly Cited
2000
Highly Cited
2000
Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity*
Fibrates and glitazones are two classes of drugs currently used in the treatment of dyslipidemia and insulin resistance (IR… Expand
Highly Cited
2000
Highly Cited
2000
Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
BACKGROUND Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2000
Highly Cited
2000
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
OBJECTIVE To provide a direct comparison of agents that raise plasma levels of high-density lipoprotein cholesterol (HDL-C) to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
1993
Highly Cited
1993
Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.
Peroxisome proliferators are postulated to elicit predictable pleiotropic responses in the liver by activating a peroxisome… Expand
Review
1990
Review
1990
Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Fenofibrate is a lipid-regulating drug which is structurally related to other fibric acid derivatives, such as clofibrate. At the… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • table III
Highly Cited
1986
Highly Cited
1986
Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators.
The structurally diverse peroxisome proliferators ciprofibrate, clofibrate, and bis(2-ethylhexyl) phthalate [(EtHx)2 greater than… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE